Market Intelligence, Clinical Progress, and High-Purity Reagents for Mast Cell-Mediated Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MRGPRX2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | MRGPRX2 Lentivirus Premade Particles (titer >10^8 TU/ml) and Promise-ORF (full-length ORF). For stable cell lines. Sequence Verified. | View MRGPRX2 Products |
| Antigen | MRGPRX2 N-terminal ECD-Fc Fusion. HEK293 expressed (Native Glycosylation). High Purity (>95%). Endotoxin <1EU/ug. | View MRGPRX2 Products |
| Benchmark Ab | Anti-MRGPRX2 (Reference Clone). Recombinant positive control for flow cytometry and blocking assays. | View MRGPRX2 Products |
| Validator | MRGPRX2 siRNA Set (3 specific sequences). For knockdown verification in cell-based degranulation assays. Endotoxin Controlled. | View MRGPRX2 Products |
| Related Target | MRGPRX1 – Primary selectivity counter-screen (42% homology, distinct nociceptive function). | View MRGPRX1 Products |
| Related Target | MRGPRX4 – Subfamily selectivity control for drug safety profiling. | View MRGPRX4 Products |
| Related Target | HRH1 – Histamine receptor H1, classic pathway comparison for mast cell activation. | View HRH1 Products |
| Related Target | IL-31 – Th2 cytokine associated with severe pruritus, synergistic target. | View IL-31 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species translation (Human/Cyno/Mouse) | Human/Mouse/Cyno MRGPRX2 ortholog lentiviruses available. Sequence identity verified (>85% conservation). |
| Subfamily selectivity (vs MRGPRX1/X3/X4) | MRGPRX family protein panel (X1, X2, X3, X4) for cross-reactivity screening. High Purity (>95%). |
| Cell surface expression & conformational integrity | Lentivirus-mediated native cell surface expression. High titer (>10^8 TU/ml) ensures >90% transduction efficiency for calcium flux assays. |
| Homolog off-target activity | High fidelity sequence verification for precise subfamily (MRGPRX1-4) counter-screening. |
| Lack of controls | Clinical Benchmark Antibodies included. |
| False positives / specificity | Validated siRNA included for knockdown specificity checks in functional assays. |
Key Genetic Variants of MRGPRX2
Known single nucleotide polymorphisms in the MRGPRX2 gene (UniProt Q96LB1):
- rs11024970 (VAR_024739)
- rs11823569 (VAR_049418)
- rs10833049 (VAR_019433)
Live MRGPRX2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Antagonist Research
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for MRGPRX2 therapeutics is intensifying, with major players shifting focus from traditional antihistamines to selective MRGPRX2 antagonists. First-generation small molecules have entered Phase II for chronic spontaneous urticaria. Next-wave R&D targets pseudo-allergic drug reactions, chronic spontaneous urticaria (CSU), and intractable pruritus. Leading companies include Escient Pharmaceuticals (EP262) and OMass Therapeutics. Modalities range from small molecules (~70% of pipeline) to monoclonal antibodies and peptide antagonists.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Escient Pharmaceuticals, OMass | Chronic Urticaria, Pruritus | Calcium Flux Assay (Need Lentivirus for Cell Lines) |
| Monoclonal Antibody | Celldex, Preclinical Biotech | Atopic Dermatitis | Receptor Binding Assay (Need Native Conformation Cells) |
| Peptide Antagonist | Academic/Emerging Biopharma | Drug-induced Anaphylaxis | Mast Cell Degranulation (Need Knockdown Controls) |